-

Schrödinger to Present at Four Investor Conferences in September

NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that management will present virtually at four investor conferences in September.

On Thursday, September 9, Schrödinger will provide a corporate overview at the Morgan Stanley 19th Annual Global Healthcare Conference at 2:00 p.m. ET. Additionally, the company is participating in the H.C. Wainwright 23rd Annual Global Investment Conference, and a pre-recorded presentation will be available on Monday, September 13, after 7:00 a.m. ET.

Schrödinger will also present at the BofA Global Healthcare Conference 2021 on Thursday, September 16, at 1:25 p.m. ET, and at the BofA Securities 2021 Tech Solutions for Drug Discovery Conference on Monday, September 20, at 11:00 a.m. ET.

The live webcasts can be accessed under "News & Events" in the investors section of Schrödinger’s website, https://ir.schrodinger.com/news-and-events/event-calendar and will be archived for approximately seven days.

About Schrödinger

Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.

Founded in 1990, Schrödinger has over 500 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com and follow us on LinkedIn and Twitter.

Contacts

Jaren Irene Madden
Schrödinger, Inc.
jaren.madden@schrodinger.com
617-286-6264

Tracy Lessor
Schrödinger, Inc.
tracy.lessor@schrodinger.com
617-519-9827

Schrödinger

NASDAQ:SDGR

Release Summary
Schrödinger today announced that it will present at four investor conferences in September.
Release Versions

Contacts

Jaren Irene Madden
Schrödinger, Inc.
jaren.madden@schrodinger.com
617-286-6264

Tracy Lessor
Schrödinger, Inc.
tracy.lessor@schrodinger.com
617-519-9827

More News From Schrödinger

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on August 12, 2026, the company granted restricted stock units (RSUs) with respect to 3,315 shares of the company’s common stock to two newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material inducement t...

Schrödinger Reports Second Quarter 2026 Financial Results

NEW YORK--(BUSINESS WIRE)--Today Schrödinger announced financial results for the quarter ended June 30, 2026....

Schrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. announced a strategic agreement with BMS to deploy Bunsen, Schrödinger's agentic AI co-scientist, within its research organization....
Back to Newsroom